ClinicalTrials.gg
RecruitingNCT06405607Psi or KetUpdated Nov 20, 2026

Psilocybin or Ketamine for Alcohol Use Disorder: An Active Comparator Trial

A Phase 2 interventional study of Psilocybin and Ketamine in Alcohol Use Disorder, Alcohol Dependence and Alcohol Abuse, sponsored by University of Iowa. Recruiting at 1 site in United States. Open to participants aged 21 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by University of Iowa · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.
Updated Nov 20, 2026Study contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
21 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 17 studies testing psilocybin in Alcoholism — 8 open to participants now, 13 under way, 1 of them phase 3. Psilocybin · Alcoholism.

Planned enrollment
8th of 17
80 · median 62
Started
2025
with 1 other
Phase 2
16 of 17
7 open now
Primary completion
2028-04
later than 9 of 12 live
Registered
12th of 17
by date

Among the 17 studies testing psilocybin in Alcoholism, this one is the 8th largest by planned enrollment, is one of 2 that started in 2025, is one of 16 in phase 2, reaches primary completion later than 9 of the 12 other live ones, and was the 12th registered.

Alcoholism

1,679 studies on the registry are indexed under Alcoholism; 333 are open to participants now.

Browse Alcoholism studies →

Open to participants now

8 of the 17 studies testing psilocybin in Alcoholism are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About psilocybin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 238 Alcoholism studies recruiting now, 85 (36%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 21 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing psilocybin in Alcoholism, or all of them as a file.
02

Study summary

This study will collect data that measures the effects of a psychedelic intervention on patients struggling with alcohol use disorder (AUD). The study design will be a double blind, randomized, active-comparator trial with two study arms. Subjects randomized to Arm 1 (n=40) will receive individual psychotherapy sessions plus a 30 mg dose of psilocybin. Arm 2 subjects (n=40) will receive individual psychotherapy sessions and a 0.75 mg/kg dose of ketamine.

03

Conditions studied

  • Alcohol Use Disorder
  • Alcohol Dependence
  • Alcohol Abuse

Browse trials for

Keywords

  • psychedelic
  • psilocybin
  • ketamine
04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Weight between 50kg and 150kg
  • No known allergies to rescue medication
  • For people capable of becoming pregnant, not pregnant and using
  • Not currently breastfeeding
  • Meets criteria for moderate to severe AUD.
  • Have at least 4 heavy drinking days (5 or more standard drinks in a day) in the past 30 days.
  • Not currently participating in formal treatment for AUD.
  • No history of a of cerebrovascular accident, asthma, or significant alcohol withdrawal history
  • No seizure disorder, coronary artery disease, heart failure, uncontrolled hypertension, insulin-dependent diabetes, pancreatitis, liver disease
  • No hallucinogen or ketamine use in past 12 months
  • No self-reported, personal, or familial history of specific psychotic disorders/episodes.
  • No serious traumatic brain injury (TBI) in the past 2 years
  • No substance use disorder other than AUD over the past 12 months
  • If taking a GLP-1 agonist, stable dosage for past 3 months
  • Family member/friend for pick-up, overnight post-drug session monitoring.
  • No MRI

Exclusion criteria

Exclusion Criteria:

Drug/medication assessment that yields: nonprescription medication use, nutritional supplement, or herbal supplement (except when approved by the study investigators), medically unstable, current medication use that has significant potential to interact with study drug (e.g., antidepressants, antipsychotics, psychostimulants, treatments for addictions, other dopaminergic or serotonergic agents, lithium, anticonvulsants, or benzodiazepines).

Psychiatric assessment that yields:1) history of severe suicide attempt, 2) current suicidality 3) first-degree relative with schizophrenia or schizoaffective disorder, 4) comorbid substance use disorder including cocaine, psychostimulant, or opioid use disorder within past 12 months 5) history of co-occurring psychotic episode/diagnosis including schizophrenia, schizoaffective disorder, schizophreniform, substance-induced psychosis, delusional disorder, or psychosis not otherwise specified, 6) high risk of adverse emotional or behavioral reaction based on the medical monitor's clinical evaluation that may also yield evidence of serious current stressors, a lack of meaningful social support, antisocial behavior, and/or serious personality disorders amongst other conditions.

Medical assessment that yields: serious abnormalities (evidence of ischemia, myocardial infarction, prolongation [QTc > .045]), serious abnormalities of complete blood count or chemistries, medical conditions that would preclude safe participation (significantly impaired liver function), or pregnancy.

MRI (pacemaker, etc.)

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Psilocybin Group (Arm 1)

    receives individual psychotherapy sessions plus a (30 mg) psilocybin session.

    Drug: Psilocybin

  • Active comparator
    Ketamine Group (Arm 2)

    receives individual psychotherapy sessions plus a (0.75 mg/kg) ketamine session

    Drug: Ketamine

Interventions

06

What researchers measure

Primary outcomes

  1. Timeline Follow-Back for Alcohol to assess change

    Quantifies daily alcohol use

    Time frame: Weekly, over the course of 16 weeks

Secondary outcomes

  1. T1rho

    Measures biological changes in the brain

    Time frame: Twice (before intervention, post intervention): at week 1 and week 16

  2. Resting state fMRI

    Measures biological changes in brain resting state global functional connectivity

    Time frame: Twice (before intervention, post intervention):: at week 1 and week 16

  3. EEG- signal complexity

    Measures electrical signal change

    Time frame: Twice (before drug administration and at peak of drug experience) during week 3

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Apr 2028, 34 months after the start.

Of 123 non-industry phase 2 interventional studies under Alcoholism, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 59. This study's planned 34 months is close to that.

Counting every sponsor, half of 135 studies reached it within 33 months; a quarter within 21 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2024
First posted
May 8, 2024
StartActual
Jun 12, 2025
Primary completionEst.
Apr 2028
CompletionEst.
Apr 2028
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Contact
Study contact changed: l•••@uiowa.edu · •••5243→l•••@uiowa.edu · •••8557. See the current contact
Nov 20, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • University of Iowa Health Care · Iowa City, United StatesContact l•••@uiowa.edu→l•••@uiowa.edu · •••8557
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Contact Study contact changed: l•••@uiowa.edu · •••5243→l•••@uiowa.edu · •••8557. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • University of Iowa Health Care · Iowa City, United StatesContact l•••@uiowa.edu→l•••@uiowa.edu · •••8557

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06405607
Lead sponsor
University of Iowa
Responsible party
Peggy C Nopoulos (Department Chair, Psychiatry, University of Iowa) — Principal investigator
First posted
May 8, 2024
Start date
Jun 12, 2025
Primary completion
Apr 2028 (estimated)
Completion
Apr 2028 (estimated)
Last update
Nov 20, 2026

Study contacts

Lauri A Jennisch, MS
Contact
lauri-jennisch@uiowa.edu
319-353-8557
Peggy C Nopoulos, MD
Contact
peggy-nopoulos@uiowa.edu
319-356-1144
Peggy C Nopoulos, MD
principal investigator · University of Iowa

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Psilocybin

Start the discussion